Although a small number of cancer patients can benefit from EGFR inhibitors as monotherapy in patients with malignancies such as breast cancer and non-small cell lung cancer, cancer cells may activate different mechanisms to evade the antitumor activity of EGFR-targeted anti-tumor drugs. Here, EGFR is linked to non-small cell lung carcinoma.